Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial

By: via Benzinga
Shares of Ligand Pharmaceuticals (NASDAQ: LGND) are down again following the results of the Phase III trial of Promacta. GSK Releases ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.